Fig. 2.
Fig. 2. Percentages of donor-derived cells in MRL/lpr mice treated with 5.5 Gy × 2 + IBM, 5.5 Gy × 2 + PV, or 5.5 Gy ×  2 + IV. / (A) Representative dot-plot profiles of BMCs, spleen cells, and HMNCs obtained from MRL/lpr mice 3 or 10 days after the treatment with 5.5 Gy × 2 + IBM, 5.5 Gy × 2 + PV, or 5.5 Gy × 2 + IV are shown. The cells were collected from the recipients and stained with donor (FITC-anti-H-2b)- and recipient (PE-anti-H-2k)-specific mAbs. (B) Kinetic analysis of donor-derived cells. Donor-derived cells in the bone marrow, spleen, and liver (HMNCs) were analyzed at the days indicated on the X-axis after staining with FITC-anti-H-2b and PE-anti-H-2k mAbs. The results are expressed as the mean ± SD of 6 mice. Symbols representing the sites of the injection of BMCs are as follows: ● represent donor-derived BMCs collected from the tibia where the donor BMCs were directly injected, and ♦ show donor-derived BMCs obtained from the femur where the donor BMCs were not injected; ▴ indicates PV, and ▪, IV.

Percentages of donor-derived cells in MRL/lpr mice treated with 5.5 Gy × 2 + IBM, 5.5 Gy × 2 + PV, or 5.5 Gy ×  2 + IV.

(A) Representative dot-plot profiles of BMCs, spleen cells, and HMNCs obtained from MRL/lpr mice 3 or 10 days after the treatment with 5.5 Gy × 2 + IBM, 5.5 Gy × 2 + PV, or 5.5 Gy × 2 + IV are shown. The cells were collected from the recipients and stained with donor (FITC-anti-H-2b)- and recipient (PE-anti-H-2k)-specific mAbs. (B) Kinetic analysis of donor-derived cells. Donor-derived cells in the bone marrow, spleen, and liver (HMNCs) were analyzed at the days indicated on the X-axis after staining with FITC-anti-H-2b and PE-anti-H-2k mAbs. The results are expressed as the mean ± SD of 6 mice. Symbols representing the sites of the injection of BMCs are as follows: ● represent donor-derived BMCs collected from the tibia where the donor BMCs were directly injected, and ♦ show donor-derived BMCs obtained from the femur where the donor BMCs were not injected; ▴ indicates PV, and ▪, IV.

Close Modal

or Create an Account

Close Modal
Close Modal